AXSM Axsome Therapeutics, Inc.

Investing.com -- Jefferies identified three biotechnology stocks that appear undervalued with strong commercial prospects despite a challenging macro environment. The firm noted that rising interest rates are pressuring small and mid-cap biotech companies, potentially shifting investor focus toward late-stage and commercial-stage names. All three of the highlighted stocks are positioned to launch products with significant peak sales potential.

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in Alzheimer’s disease agitation, while management expects operating expenses to remain relatively stable in the

Axsome Therapeutics has turned into a much bigger story on the market over the past few years, and the question now is whether the current share price can be squared with the sales that support it. For investors watching the recent swings, the key issue is how much revenue power is already baked into today’s valuation. Over the past 5 years the stock has delivered a very large total return of about 7x, which puts a lot of focus on whether that move is backed by the company’s underlying sales...

Earlier this week, Axsome Therapeutics highlighted new clinical data in major depressive disorder and Alzheimer’s disease agitation at Psych Congress 2026 in New Orleans, including outcomes for its dextromethorphan-bupropion therapy. By showcasing fresh and encore data across its psychiatry and neurology portfolio, Axsome put the breadth of its central nervous system pipeline in front of a clinically focused audience that can influence real-world adoption. We’ll now examine how this new...

Axsome Therapeutics (NASDAQ:AXSM) executives highlighted growth across its commercial portfolio, an expanded sales force and multiple late-stage clinical programs during the H.C. Wainwright 28th Annual Global Investment Conference. Chief Operating Officer Mark Jacobson said the company has three ma

Axsome Therapeutics (NasdaqGM:AXSM) reported new clinical data in major depressive disorder and Alzheimer’s disease agitation at a leading psychiatry congress. The presentations focused on key programs in Axsome’s central nervous system pipeline aimed at treating mood and neuropsychiatric symptoms. Management highlighted how the new findings may inform future study designs and regulatory interactions for these indications. These fresh data in depression and Alzheimer’s agitation only capture...

Or are its best days in the rearview mirror?

One company is growing a commercial drug business with limited margin for error on the path to profitability. The other has a platform that proved itself at global scale and keeps finding new diseases to target.

Axsome is generating revenue from approved drugs but missing estimates and widening losses. Revolution Medicines just changed the standard of care for one of the deadliest cancers in existence.

The stock slipped about 15% over the past three months.

Citing Bloomberg Symphony figures for the 30-milligram starter dose used when doctors begin treatment, a Mizuho analyst said new prescriptions for Auvelity rose 32% from July to August.

One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses.

Axsome is already selling drugs with 65% revenue growth, while Viking bets on obesity treatments still in trials, a classic choice between proven sales and blockbuster potential.

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AXSM begins dosing in the phase III SUMMIT study investigating AXS-05 for treating smoking cessation in adults.

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

The company has also crushed broader equities over the past five years.

Check out our earnings calendar for this week, as well as our previews and recaps of the more noteworthy reports.

AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.

Axsome Therapeutics earnings event and why it matters Axsome Therapeutics (AXSM) just reported second quarter 2026 results, with revenue of US$218.38 million and a net loss of US$51.31 million. Earnings per share were a loss of US$0.99, matching analyst expectations. For the first six months of 2026, Axsome Therapeutics reported revenue of US$409.58 million and a net loss of US$115.86 million. Loss per share over this period was US$2.25 on both a basic and diluted basis. See our latest...

Axsome Therapeutics has delivered a very large 5 year return while the current valuation checks point to a stock that now looks closer to fairly priced than clearly cheap. The market has rewarded the story, so the question is whether the present price still leaves enough room for longer term investors to be comfortable. Axsome Therapeutics has returned about 9.4x over the past 5 years, which puts the recent share price firmly at the higher end of its historical range for many...

The FDA has already accepted the company’s application seeking the greenlight for AXS-12.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) shares rose 2.

While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Axsome Therapeutics (NASDAQ:AXSM) reported second-quarter 2026 net product revenue of $218 million, up 46% from a year earlier, as sales of AUVELITY and SUNOSI increased and prescription demand for SYMBRAVO continued to build. The company posted a net loss of $51.3 million, or $0.99 per share, comp

Axsome (AXSM) delivered earnings and revenue surprises of 0.00% and -2.74%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The benchmark US stock measures were mostly pointing higher before the opening bell Monday as trader

Alpha Cognition Inc. (ACOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of +56.52% and +98.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Axsome (AXSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.

Gilead (GILD) delivered earnings and revenue surprises of +4.53% and +5.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

These innovative biotech companies should reap the benefits of their breakthroughs.

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ARDX, BDORY and AXSM have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2026.

ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “Small Cap Growth Strategy”. A copy of the letter can be downloaded here. The Russell 2000 Growth Index increased by 25.6% in the second quarter, marking its third-best quarterly performance in two decades. The rally was fueled by enthusiasm for AI, strength […]

Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls

Jazz Pharmaceuticals (JAZZ) is back in focus after Axsome Therapeutics disclosed an FDA filing for AXS-12 in narcolepsy, highlighting Sunosi’s move from Jazz’s portfolio and refocusing attention on Jazz’s broader sleep-disorder franchise. See our latest analysis for Jazz Pharmaceuticals. Investors have responded to Jazz Pharmaceuticals’ sleep and oncology pipeline story with a 9.1% 1 month share price return and a 42.3% 5 year total shareholder return, while the 1 year total shareholder...

AXSM advances AXS-12 toward potential approval after the FDA accepts its NDA for cataplexy in narcolepsy and sets a May 2027 decision date.